Prostaglandin F2α FP receptor inhibitor reduces demyelination and motor dysfunction in a cuprizone-induced multiple sclerosis mouse model

Prostaglandin F2α FP receptor inhibitor reduces demyelination and motor dysfunction in a cuprizone-induced multiple sclerosis mouse model
复制标题

DOI:
10.1016/j.plefa.2014.08.004
复制
发表时间:
2014-11-01
影响因子:
3
通讯作者:
Yoshikawa, K.
Yoshikawa, K.
中科院分区:
医学4区
文献类型:
--
作者:
Iwasa, K.;Yamamoto, S.;Yoshikawa, K.

文献摘要

被引文献

相似文献

此前,我们已经证明前列腺酰胺/PGF合酶在髓鞘和培养的少突胶质细胞中组成型表达,其催化前列腺素(PG)H-2还原为PGF(2α),表明PGF(2α)在髓鞘形成少突胶质细胞中具有功能意义。为了研究 PGF(2α)/FP 受体信号传导对脱髓鞘的影响,我们给暴露于铜宗的小鼠(多发性硬化症模型)施用 FP 受体激动剂和拮抗剂。小鼠被喂食含有 0.2% 铜宗的饮食 5 周,这会诱导严重的脱髓鞘、胶质细胞活化、促炎细胞因子表达和运动功能障碍。给予 FP 受体拮抗剂 AL-8810 可减轻铜宗诱导的脱髓鞘、神经胶质活化和胼胝体中 TNF α 的表达,并改善运动功能。这些数据表明,在铜宗诱导的脱髓鞘过程中,PGF(2α)/FP 受体信号传导有助于神经胶质活化、神经炎症和脱髓鞘,从而导致运动功能障碍。因此,FP 受体抑制可能是多发性硬化症的有效对症治疗。 (C) 2014 Elsevier Ltd. 保留所有权利。
Previously, we have demonstrated that prostamide/PGF synthase, which catalyzes the reduction of prostaglandin (PG) H-2 to PGF(2 alpha) is constitutively expressed in myelin sheaths and cultured oligodendrocytes, suggesting that PGF(2 alpha) has functional significance in myelin-forming oligodendrocytes. To investigate the effects of PGF(2 alpha)/FP receptor signaling on demyelination, we administrated FP receptor agonist and antagonist to cuprizone-exposed mice, a model of multiple sclerosis. Mice were fed a diet containing 0.2% cuprizone for 5 weeks, which induces severe demyelination, glial activation, proinflammatory cytokine expression, and motor dysfunction. Administration of the FP receptor antagonist AL-8810 attenuated cuprizone-induced demyelination, glial activation, and TNF alpha expression in the corpus callosum, and also improved the motor function. These data suggest that during cuprizone-induced demyelination, PGF(2 alpha)/FP receptor signaling contributes to glial activation, neuroinflammation, and demyelination, resulting in motor dysfunction. Thus, FP receptor inhibition may be a useful symptomatic treatment in multiple sclerosis. (C) 2014 Elsevier Ltd. All rights reserved.